Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

CING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed ...

Originally published on talker.news, part of the BLOX Digital Content Exchange .

The parts of the brain that are needed to remember words, and how these are affected by a common form of epilepsy, have been ...

The subtleties involved here reflect the fact that the brain’s dizzying complexity means it’s rarely possible to draw simple conclusions. Even in this case, where a basic interpretation might be that ...

KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Researchers have discovered how specific brain circuits process empathy, showing that witnessing others in pain activates the ...

Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AMN Healthcare Services (AMN – Research ...